Background: Sunitinib is a standard of care for metastatic renal cell carcinoma (mRCC). Hypothyroidism is frequently observed under sunitinib therapy. This study was conducted to prospectively determine the correlation between thyroid function and progression-free survival (PFS) in this population.
introduction Sunitinib, a multitarget tyrosine kinase inhibitor, affects different pathways involved in angiogenesis, apoptosis or cell proliferation, such as vascular endothelial growth factor (VEGF) receptor-1, -2 and -3; platelet-derived growth factor receptor (PDGFR) a/b; c-KIT receptor; FMS-like tyrosine kinase 3 (FLT-3), colony-stimulating factor 1 receptor (CSF1R) and RET [1] . Sunitinib is the standard of care for patients with metastatic renal cell carcinoma (mRCC) in first-line [2] or in second-line therapy after cytokines failure [3] and gastrointestinal stromal tumours (GIST) in second-line therapy after imatinib failure [4] .
Sunitinib is generally well tolerated and the frequency of grade 3 and 4 clinical toxic effects and laboratory abnormalities is relatively low (<10% and £16%, respectively) [2] . Fatigue, diarrhoea, anorexia, oral changes, skin toxicity and hypertension are the most relevant clinical side-effects. In a large phase III trial, the incidence of fatigue was 51% [2] . Some authors have shown that this fatigue might be at least partially induced by hypothyroidism [5] .
Thyroid function abnormalities have been found in 40%-85% of patients treated for mRCC or imatinib-refractory GIST [5] [6] [7] [8] [9] . Sunitinib-induced hypothyroidism has been observed 4-50 weeks after therapy initiation and its incidence usually increases with prolonged treatment [7] [8] [9] . Despite several explanatory hypotheses, the true mechanisms of this side-effect remain unclear. It is of note that hypothyroidism has been correlated with better outcome in many malignant diseases such as breast carcinoma, head and neck cancer and gliomas [10] [11] [12] . Nevertheless, its influence on renal cell carcinoma outcome has been poorly documented [9] . Hypothyroidism management in renal cell cancer patients is thus not clearly defined.
We report our experience of a prospective observational multicentre study designed to estimate the incidence of sunitinibinduced thyroid dysfunction and the influence of dysthyroidism on progression-free survival (PFS) in mRCC patients.
patients and methods patients
One hundred and eleven patients with pathologically proven clear cell mRCC treated in two tertiary referral centres were included from October 2005 to December 2008. At baseline, all patients underwent computed tomography (CT) scan, bone scan and blood tests. They all had adequate haematological, renal, hepatic and cardiac function before treatment.
Patients received sunitinib 50 mg per day in repeated 6-week cycles, consisting of 4 consecutive weeks of sunitinib followed by a 2-week rest period. Dose adjustment was done depending on toxicity as recommended.
assessments
Tumour response was evaluated by the investigators every 12 weeks with thorax, abdomen and pelvic CT scan, and bone scan if necessary. Responses were evaluated according to the RECIST v1.0.
PFS was defined from the date of sunitinib introduction to radiologically confirmed progression or death under treatment. Overall survival was the time from sunitinib introduction to death. Follow-up was the time from sunitinib introduction to the date of last news for patients without progression under treatment. Patients lost to follow-up or those who discontinued sunitinib treatment before progression were censored.
Biological thyroid function evaluation comprised (Thyroxine) T4 and thyroid-stimulating hormone (TSH) before treatment and at day 1 of each 6-week cycle. Only patients with normal baseline TSH were included in final analyses. Thyroid hormone replacement therapy was accomplished by dedicated endocrinologists according to the following biological abnormalities or clinical presentation: TSH levels above the upper limit of the normal range, with or without clinical symptoms (overt or subclinical hypothyroidism).
statistical analysis
The association of thyroid dysfunction status with PFS was assessed with the landmark method [13] . We determined each patient's thyroid function status at some fixed time point (landmark time). The landmark method corrects for a systematic bias that results from the categorisation of early progressive patients with nonassessable thyroid function among the normal thyroid function group. Therefore, patients who progressed or were censored before the landmark time were excluded from the analysis. Logrank test was used to assess the association between thyroid function status at the landmark time (Group 1 = normal thyroid function [NTF] and Group 2 = thyroid dysfunction [TDF]) and PFS. The landmark time was fixed at 6 months after the initiation of sunitinib because a 6-month period was considered sufficient to observe a minimum of sunitinib-induced dysthyroidisms, while not excluding an undue proportion of patients with progressive disease.
To explore if the survival difference was specific of this evaluation time or was time dependent, we compared the 2-year PFS rates between the groups resulting from landmark analyses carried out at different evaluation times (from 1 to 12 months after sunitinib introduction) [14] .
Comparisons between groups and histoclinical factors were carried out using the Fisher's exact test for qualitative variables and the chi-square test for quantitative variables.
Univariate and multivariate analyses were done using Cox regression analysis. The variables tested in univariate analyses included age of patients, sex, Memorial Sloan-Kettering Cancer Centre (MSKCC) classification, achievement of nephrectomy before sunitinib introduction, pathological tumour size, histological grades according to Fuhrman score, number of treatment lines before sunitinib and thyroid function status defined with the landmark method previously described. Multivariate analysis was done by incorporating all variables with a P-value £ 0.05 in univariate analysis.
The P-values were based on the Wald test, and patients with one or more missing data regarding the retained variables were excluded.
All analyses were carried out using SAS/STAT software, version 9.1.3 of the SAS System for PC (SAS Inc., Cary, NC).
This prognostic study was carried out according to the REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria [15] .
results

patients' characteristics
Out of 111 patients with metastatic clear cell renal carcinoma, 102 had NTF at baseline; their characteristics are described in Table 1 The landmark population (Table 1 ) was close to the whole cohort, except fewer patients with progression as best response.
dysthyroidism incidence under sunitinib therapy
Baseline TSH measurements were available for all patients and 102 had NTF (91.9%). Of these 102 patients, 54 (53%) developed TDF under sunitinib therapy. The abnormality was hypothyroidism in 51 (95%), out of which 46 (91%) received L-thyroxine replacement. Half of our patients presented thyroid function alterations after a treatment duration of 9.2 months ( Figure 1B) ; median time to TDF was 5.4 months [0.6-22.2 months].
dysthyroidism influence on PFS
When exploring the influence of dysthyroidism on PFS, 33 out of the 102 patients were excluded from the analysis due to the landmark time fixed at 6 months (progressive or censored patients) ( Figure 2 ). Prognosis parameters were equally distributed between NTF and TDF groups ( Table 2 ). Response to treatment was comparable between both groups (P = 0.71). Univariate analysis showed that PFS was influenced in this landmark cohort by number of treatment lines before sunitinib introduction and by the main prognostic classifier used worldwide for renal clear cell carcinoma management, i.e. the MSKCC risk classification (Table 3) . These both factors remained significant in multivariate analysis. Moreover, outcome was not modified by thyroid function status: me n PFS was 15.9 months for NTF patients versus 18.9 months for TDF patients (P = 0.94, hazard ratio [HR] = 1.02, 95% confidence interval [CI] = 0.54-1.93, log-rank test) ( Figure 3 ).
To avoid a time-dependent bias, we assessed the 2-year PFS rate difference between the two groups resulting from landmark analyses carried out at 12 evaluation times. No significant 2-year PFS difference could be observed between NTF and TDF groups ( Figure 4 ).
dysthyroidism impact on outcome according to initial prognosis and previous therapy
We then explored TDF prognostic value within the subgroups defined by the two factors significantly associated with outcome in our set: MSKCC classification and treatment before sunitinib.
Prognostic factors were equally distributed between NTF and TDF groups. However, there were slightly more MSKCC low-risk patients in the TDF group (P = 0.09, v 2 test). Thus, we assessed the prognostic impact of dysthyroidism inside each MSKCC class. In the low-risk group, 13 patients developed dysthyroidism during the first 6 months of treatment; median PFS was 28.1 months for NTF patients versus 19.9 months for TDF patients (P = 0.27, log-rank test). For the 34 intermediaryrisk patients (nine dysthyroidisms), median PFS was 12.8 months in the NTF subgroup versus 14.9 months in the TDF subgroup (P = 0.99, log-rank test). We observed the same results for the six high-risk patients (two dysthyroidisms).
As number of therapies before sunitinib was an independent prognostic factor in our cohort, we finally focused on the correlation between dysthyroidism influence on outcome and treatment line. Out of the 69 patients, 36 had received a treatment before sunitinib. Patients who received a cytokine-based therapy were 32, including 12 patients who developed dysthyroidism under sunitinib treatment before the landmark time (6 months); four patients received sorafenib as first-line treatment (two dysthyroidism). Among the 33 patients receiving sunitinib as first-line treatment, 10 patients (7) presented with TDF. Dysthyroidism was not more frequent in previously treated patients as compared with treatment-naive ones (P = 0.62, Fisher's exact test). In the first-line treatment group, median PFS was 9.8 months in the NTF subgroup versus 10.2 months in the TDF subgroup (P = 0.57, log-rank test). The results were similar in previously treated patients (P = 0.32, logrank test).
discussion
We report in this prospective observational multicentre study that 52.9% of our patients treated with sunitinib for metastatic renal clear cell cancer developed dysthyroidism with a median time to appearance of 5.4 months. This high incidence rate is in agreement with published data [7] [8] [9] and confirms sunitinib effect on thyroid function. We also observed in this study, where most of the biological hypothyroidisms were supplemented, that there was no PFS difference associated with thyroid function alteration. A landmark analysis, that avoided misclassification of early progressive patients, showed similar PFS in patients with or without TDF (18.9 versus 15.9 months, respectively, P = 0.94). It is of note that this observation could be made independent of previous treatments (sunitinib as firstline therapy or one or more previous treatments of mRCC) or MSKCC risk group. The response rates observed in our study corroborate those of already published data with a clinical benefit (objective response plus stable disease) of 79.5% in our study and a median PFS of 11.7 months for our whole cohort, similar to the ones (87% and 11 months, respectively) reported in the phase III trial [16, 17] . Moreover, initial dysthyroidism rate (8%) was in agreement with that observed in the general population [18] . Limitations of our study were the limited size of the cohort and the observational design, which could be improved with further comparative studies. Our choice to supplement all patients with TSH enhancement may also be criticised, as well as the lack of exhaustive thyroid exploration with systematic thyroid ultrasonography and antibodies assessment, that could have been useful for understanding the mechanisms by which sunitinib induces TDF, even if they are not recommended nowadays.
One of the main adverse events of anticancer treatments for mRCC is fatigue. This side-effect is particularly frequent under sunitinib therapy: 54% for all grades and 11% for grades 3 and 4 [17] . A major issue is to determine the aetiology of this possibly multifactorial asthenia: disease-related symptom? Direct therapeutic adverse event? Hypothyroidism consequence? Anyway, since at least one part of this symptom can be explained by a curable cause, such as sunitinib-induced hypothyroidism, clinicians should be aware of this problem.
Hypothyroidism was already described under cytokine therapy with occurrence rates from 15% under interferon-a [19] to 21% and 47% under interleukin 2 therapy [20, 21] . Several studies have also described the incidence and modalities of dysthyroidism under sunitinib treatment. It was firstly observed by Desai et al. [7] that 62% of their 42 patients treated by sunitinib (for imatinib-resistant GIST) developed TSH abnormalities during treatment, dysthyroidism increasing with treatment duration. Similarly, Rini et al. [8] found that 85% of their 66 patients treated with sunitinib for mRCC presented with biological thyroid function abnormalities including 46 patients with elevated TSH levels. Retrospective analysis of the patients included in prospective pivotal trials [17] [18] [19] [20] [21] [22] found that 18% developed clinical hypothyroidism. Finally, Wolter [9] showed in a prospective evaluation of sunitinib-induced hypothyroidism among renal cell carcinoma or GIST patients that nearly 60% developed a TSH increase with 27% needing Figure 2 . Landmark study flow chart. Out of the 102 initially euthyroid patients, 33 were excluded for analysis because of early progression or censorship; the remaining 69 patients were split into two groups according to their thyroid status after a 6-month treatment duration. hormone replacement as recommended in general population guidelines [18] [19] [20] [21] [22] [23] . Therefore, dysthyroidism incidence in our study (53%) is close to already published ones. Hypotheses have been formulated to explain the mechanisms of dysthyroidism induction by tyrosine kinase inhibitors: thyroid peroxidase inhibition [6] and reduction of fenestration number in thyroid capillary and enhancement of capillary regression via VEGF inhibition [24] . Other authors suggested that sunitinib can lead to a destructive thyroiditis through follicular cell apoptosis [7, 8] , lymphocytic thyroiditis [25] or block iodine 123 uptake [5] . Nevertheless, none of these hypotheses is currently clearly established.
While clinical management of hypothyroidism is unclear in cancer patients, it is well defined in general population [18] . There is no clear benefit to treat patients with subclinical hypothyroidism, i.e. patients with serum TSH concentration above the upper limit of the reference range (4.5 mIU/l) when serum-free T4 (FT4) concentration is within its reference range; whereas subjects with overt hypothyroidism (high TSH combined with low FT4) benefit from replacement therapy. Nevertheless, no recommendation is established for cancersuffering hypothyroid patients in the different published studies. Wolter gave replacement therapy in case of overt hypothyroidism or two consecutive TSH measurements above original articles Annals of Oncology 10 mIU/l associated with symptoms compatible with hypothyroidism. We chose at study initiation to supplement all hypothyroidisms (overt and subclinical hypothyroidisms) in order to treat all putative hypothyroidism-related symptoms (notably fatigue). Another reason for this decision was the quick evolution of sunitinib-induced hypothyroidism: TSH frequently exhibits a two-to threefold increase during a single cycle of treatment. Nevertheless, this may have resulted in an excess of treatment, which may have enhanced the putative (negative) effect of hormone supplementation on outcome. This aspect will have to be taken into account in further studies.
Indeed, the influence of hypothyroidism on cancer survival has been suspected in several fields [26] . Elements exist to suggest that T3 and T4 may be permissive for tumour growth and may reduce survival in recurrent brain tumours [10] and in head and neck cancer [12] . Hercbergs showed that propylthyuracil-induced hypothyroidism enhanced antitumour effect of high tamoxifen (by insulinlike growth factor inhibition) with higher survival for hypothyroid patients. Similarly, hypothyroidism was observed to be associated with reduced incidence, less aggressive (more localised disease) and older age diagnosed breast cancers [11] . Hypothyroidism protective effect may be explained by thyroid hormone activity (mainly T4) on cancer cells proliferation via interaction with integrin family (a2b3) and epidermal growth factor, insulin-like growth factor 1 receptor phosphorylation, anti apoptotic pathways (mitogen-activated protein kinase) and angiogenesis via Fibroblast growth factor [27] . Hypothyroidism protective effect on renal cell cancer survival has also been reported. In the Wolter et al. study [28] , median PFS was respectively 10.3 and 3.6 months with and without thyroid function abnormalities (P = 0.047) and there was a trend towards an overall survival improvement: 18.2 months with TDF versus 6.6 months in the euthyroid group (P = 0.13). Schmidinger et al. [29] recently published results describing that hypothyroidism occurring under tyrosine kinase inhibitors (sunitinib and sorafenib) treatment is a predictive marker of treatment efficacy, with a significant improvement of overall survival (it was not significant for PFS) for hypothyroid patients. Garfield et al. [30] made two hypotheses to explain this improvement: first, a direct action of thyroid hormone on cancer cell proliferation, cancer cell growth and angiogenesis; second, the association between sunitinib Figure 3 . Progression-free survival (PFS) according to thyroid function using a landmark-derived analysis with a 6-month cut-off (n = 69). PFS was 15.9 months for euthyroid patients versus 18.9 months for patients who developed a thyroid dysfunction under sunitinib. Figure 4 . Two-year progression-free survival (PFS) rates according to thyroid status screened at different landmark times (from 1 to 12 months) after sunitinib introduction. Two-year PFS rates were not significantly different between patients of the normal thyroid function (NTF) group and those with thyroid dysfunction (TDF). NS: non significant. plasma levels and TDF occurrence may suggest that dysthyroidism (TSH levels mainly) could be a surrogate marker for sunitinib efficacy. This putative hypothyroidisminduced protective effect led the authors to introduce the question of hormone replacement therapy modalities in carcinoma-suffering patients receiving tyrosine kinase inhibitors treatment [31] . If hormone replacement induces a survival disadvantage by cancelling hypothyroidism protective action, clinicians will have to weigh up carefully the pros and cons of hormone substitution under sunitinib therapy, notably if their patients do not present with clinical symptoms.
However, the protective effect of TDF suggested by Wolter and Schmidinger need to be confirmed in further studies. Indeed, statistical methods used in these articles may be criticised. For the Wolter study, the first bias comes from the inclusion of early progressive patients in the euthyroid group, resulting in a risk of misclassification. The landmark analysis allows us to exclude these patients because we observed that dysthyroidism occurred not so early in natural cancer history. Patients who progressed or died in the first months because of their renal cancer could have no thyroid abnormality not because their thyroid was not altered by the treatment but because this adverse event will appear later in their natural history. The second bias was that all hypothyroidism were taken into account, whatever the dysthyroidism appearance time. This issue prevents to project this observation in clinical routine practise as follows: prognostic or predictive markers can be used in daily practise only if they are evaluated at a previously defined time used by all practitioners, i.e. diagnosis time for prognostic markers; just before or at a specific time after treatment initiation for predictive ones. We cancelled this second bias in our study by defining a landmark time, defining the thyroid function status at a particular time: only events occurring after this time were used in prognosis evaluation.
In Schmidinger et al. [29] , the authors noted that hypothyroidism did not significantly improve PFS but had a prognostic value to predict overall survival. However, they did not specify what were the therapies carried out after progression under sunitinib or sorafenib, if these therapies were equally balanced between hypothyroid and euthyroid patients. This lack is important because these treatments could have modified overall survival. We report only PFS analyses in our study because of the heterogeneity of treatments received after sunitinib in our cohort. This resulted in several small size subsets, which could not be statistically analysed.
Using landmark we did not find a PFS difference according to thyroid function: 15.9 months for NTF patients versus 18.9 months for dysthyroid patients (P = 0.94). This absence of survival difference was still observed irrespective of initial prognostic factors (MSKCC classification) or previous treatments. No survival improvement could be correlated with thyroid function neither in low-risk (P = 0.27), intermediary-risk (P = 0.99) nor high-risk patients. Even if there was a trend in survival benefit for NFT patients in the low-risk group (P = 0.27), no conclusion can be done because of the small number of patients analysed in this subgroup. In the same way PFS was not modified by TDF in treatment-naive patients (P = 0.57) or in previously treated ones (P = 0.32). Since we chose to give hormone replacement as soon as the patients presented with TSH abnormality with or without clinical symptoms, the following question should be asked: does TDF really not affect PFS or does thyroid replacement cancel the clinical benefit induced by hormone abnormality? In other words, is it possible to improve the patients' quality of life by alleviating the hypothyroidism-induced fatigue without impairing clinical outcomes?
Therefore, further studies are needed to determine whether and how hormone replacement can modify sunitinib treatment outcomes in comparing survival with or without substitution in mRCC patients presenting with dysthyroidism (in particular subclinical hypothyroidism). This issue may be explored with the management that we currently use, based on the new standard of care that will be published soon and that are close to those of general population [23] : substitution in case of TSH higher than 10 mU/l or between 5 and 10 mU/l with clinical symptoms that can be linked to hypothyroidism.
conclusion
This study confirms the high frequency of sunitinib-induced dysthyroidism in mRCC. Biological TDF occurs in more than half of sunitinib-treated patients. Nevertheless, it appears that patients with TDF and replacement therapy do not have a different PFS compared with patients without TDF.
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